Aldo Caltavituro

Dr. Aldo Caltavituro

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
RBRoberto Buonaiuto
Roberto Buonaiuto
GNGiuseppe Neola
Giuseppe Neola
SCSabrina Chiara Cecere
Sabrina Chiara Cecere
ACAldo Caltavituro
Aldo Caltavituro
ACAmedeo Cefaliello
Amedeo Cefaliello
CACarmine De Angelis
Carmine De Angelis
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies worldwide. Fortunately, recent advances in OC biology and the discovery of novel therapeutic targets have led to the development of novel therapeutic agents that may improve the outcome of OC patients. The glucocorticoid receptor (GR) is a ligand-dependent transcriptional factor known for its role in body stress reactions, energy homeostasis and immune regulation. Notably, evidence suggests that GR may play a relevant role in tumor progression and may affect treatment response. In cell culture models, administration of low levels of glucocorticoids (GCs) suppresses OC growth and metastasis. Conversely, high GR expression has been associated with poor prognostic features and long-term outcomes in patients with OC. Moreover, both preclinical and clinical data have shown that GR activation impairs the effectiveness of chemotherapy by inducing the apoptotic pathways and cell differentiation. In this narrative review, we summarize data related to the function and role of GR in OC. To this aim, we reorganized the controversial and fragmented data regarding GR activity in OC and herein describe its potential use as a prognostic and predictive biomarker. Moreover, we explored the interplay between GR and BRCA expression and reviewed the latest therapeutic strategies such as non-selective GR antagonists and selective GR modulators to enhance chemotherapy sensitivity, and to finally provide new treatment options in OC patients.

14 November 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
RBRoberto Buonaiuto
Roberto Buonaiuto
FMFederica Martorana
Federica Martorana
PMPaola Marino
Paola Marino
FMFederica Mangiacotti
Federica Mangiacotti
ACAldo Caltavituro
Aldo Caltavituro
CACarmine De Angelis
Carmine De Angelis

13 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAldo Caltavituro
Aldo Caltavituro
RBRoberto Buonaiuto
Roberto Buonaiuto
EPErica Pietroluongo
Erica Pietroluongo
RMRocco Morra
Rocco Morra
FSFabio Salomone
Fabio Salomone
MGMario Giuliano
Mario Giuliano
Sarcomas of the thoracic cavity are rare entities that predominantly affect children and young adults. They can be very heterogeneous encompassing several different histological entities. Ewing Sarcoma (ES) can potentially arise from every bone, soft tissue, or visceral site in the body. However, it represents an extremely rare finding when it affects the thoracic cavity. It represents the second most frequent type of thoracic sarcoma, after chondrosarcoma. ES arises more frequently in sites that differ from the thoracic cavity, but it displays the same biological features and behavior of extra-thoracic ones. Current management of ES often requires a multidisciplinary treatment approach including surgery, radiotherapy, and systemic therapy, as it can guarantee local and distant disease control, at least transiently, although the long-term outcome remains poor. Unfortunately, due to the paucity of clinical trials purposely designed for this rare malignancy, there are no optimal strategies that can be used for disease recurrence. As a result of its complex biological features, ES might be suitable for emerging biology-based therapeutic strategies. However, a deeper understanding of the molecular mechanisms driving tumor growth and treatment resistance, including those related to oncogenic pathways, epigenetic landscape, and immune microenvironment, is necessary in order to develop new valid therapeutic opportunities. Here, we provide an overview of the most recent therapeutic advances for ES in both the preclinical and clinical settings. We performed a review of the current available literature and of the ongoing clinical trials focusing on new treatment strategies, after failure of conventional multimodal treatments.

6 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
PPPietro De Placido
Pietro De Placido
RRRossana Di Rienzo
Rossana Di Rienzo
EPErica Pietroluongo
Erica Pietroluongo
CMClaudia Martinelli
Claudia Martinelli
MTMargherita Tafuro
Margherita Tafuro
MGMario Giuliano
Mario Giuliano
Hormone receptor-positive (HR+)/HER2-negative (HER2-) early-stage breast cancers (EBC) are treated with adjuvant endocrine therapy (ET), with chemotherapy (CT) reserved for high-risk cases. Obesity is linked to increased recurrence risk. The Oncotype DX® assay predicts prognosis and CT benefit. The PRO BONO study evaluated Oncotype DX test's impact on treatment decisions and explored associations between genomic risk, tumor features, and patient metabolic profiles. Patients with HR+ /HER2-EBC undergoing Oncotype DX testing were enrolled. Body mass index (BMI), tumor characteristics (ER, PR, Ki67, grading, size, nodal status), a large panel of metabolic analytes, and Oncotype DX Recurrence Score® (RS) results were collected. Treatment recommendations (ET vs CT-ET) were recorded pre- and post-Oncotype DX, and concordance was determined using Cohen's Kappa. Associations were tested using Chi-Square test and Spearman Correlation. Of the 248 EBC patients (2019-2021), Oncotype DX testing reduced CT use by 47.7 %. Higher RS positively correlated with serum triglycerides and inversely with GIP (all p < 0.05). No significant association was found between patient BMI and RS result. Conversely, tumor size positively correlated with BMI (p = 0.0286) and with serum levels of leptin (p = 0.0079), PAI-1 (p = 0.0083), C-peptide (p = 0.0124), GIP (p = 0.0036), GLP-1 (p = 0.0476), glucagon (p = 0.0224), and insulin (p = 0.0327). A BMI≥ 30 and higher GLP-1 levels (>148.85pg/ml) were independently associated with increased odds of having larger tumor size (>2 cm). Recurrence Score result significantly impacts treatment decisions in HR+ /HER2-EBC. RS result was not associated with BMI, although unfavorable metabolic profiles and obesity-related markers correlated with larger tumors. These findings highlight the need to further investigate the link between metabolic profiles and breast cancer biology.

29 May 2026 in The Breast
Verified
Journal Article
Open access
RBRoberto Buonaiuto
Roberto Buonaiuto
FMFederica Pia Mangiacotti
Federica Pia Mangiacotti
FGFabiola Giudici
Fabiola Giudici
MTMargherita Tafuro
Margherita Tafuro
RSRoberta Scarfetta
Roberta Scarfetta
Fabio PuglisiFabio Puglisi
Fabio Puglisi
The management of patients with high-risk early breast cancer (eBC) requires balancing between clinical benefit and toxicity. Number Needed to Treat (NNT) and Number Needed to Harm (NNH) may provide a clinically intuitive framework to assess benefit–risk profiles, but their use in eBC has not been systematically explored. We analysed 10 phase II–III randomized clinical trials (RCTs) of treatment escalation strategies in patients with mid to high-risk eBC. To ensure consistency and cross-trial comparison, invasive disease-free survival (IDFS), disease-free survival (DFS), event-free survival (EFS), and overall survival (OS) were extracted at 3 and 5 years (y). Safety outcomes included any-grade (G) and G ≥ 3 adverse events (AEs), G5 AEs, and treatment discontinuation (TD). Absolute risk reduction (ARR) and absolute risk increase (ARI) were used to calculate NNT and NNH, respectively, reported with 95% CIs. In patients with the HER2+ eBC, KATHERINE showed the most favorable efficacy, with NNTs of 9 and 8 for IDFS at 3 and 5 years, respectively, and a NNT of 27 for OS at 5 years. APHINITY reported the most favorable safety profile, with the highest NNHs for G ≥ 3 AEs (15) and TD (80). In patients with TNBC, CREATE-X reported the lowest NNTs for DFS (7 at both 3 and 5 years). The most favorable results in OS were observed in OlympiA (NNT 26) and KEYNOTE-522 (NNT 20). Regarding safety, KEYNOTE-522 achieved the most favorable NNH for G ≥ 3 AEs (26), while OlympiA showed the best NNH for TD (16). In patients with HR+/HER2− eBC, OlympiA showed the strongest efficacy results, with the lowest NNTs for IDFS at 3 (10) and 5 years (9), as well as for OS at 5 years (26). The most favorable NNHs were reported for G ≥ 3 AEs in OlympiA (8) and for TD in monarchE (19). NNT and NNH provide intuitive metrics to communicate benefit–risk trade-offs in high-risk eBC, although their variability across trials, subgroups, and timepoints requires cautious interpretation.

22 May 2026 in European Journal of Cancer
Verified
Journal Article
Open access
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
VLVincenzo Di Lauro
Vincenzo Di Lauro
DMDaniel Morchón
Daniel Morchón
SNSabrina Nucera
Sabrina Nucera
LFLuis Figuero-Pérez
Luis Figuero-Pérez
Francesco SchettiniFrancesco Schettini
Francesco Schettini
Genomic assays (GA) guide chemotherapy (CT) use in stage I-II endocrine receptor-positive (ER+)/HER2-negative (HER2-) breast cancer (BC). In tumors N0/intermediate-risk or N1/low-to-intermediate-risk, randomized trials with OncotypeDX® showed a CT benefit only for women aged≤ 50 years/premenopausal. Comparable data for the Prosigna® GA are lacking. We retrospectively included 567 women aged≤ 50 years with stage I-II ER+ /HER2 - BC tested with Prosigna® across 10 hospitals in Spain/Italy (2014-2023). Patients received endocrine therapy (ET) with/without (neo)adjuvant CT. Event-free survival (EFS) was analyzed using Kaplan-Meier curves, log-rank tests, and Cox regression. Propensity score matching (PSM) was applied. 5-year EFS rates were numerically compared with those of OncotypeDX® trials. Of 567 patients, 73.7% were N0 and 26.3% N1, 39.7% were Prosigna risk-of-relapse (ROR)-low (RL), 33.0% ROR-intermediate (RI), 27.3% ROR-high (RH) and 48.3% received CT. CT independently improved EFS in N0/RI and N1/RL-RI (5-year EFS 97.9% vs. 86.6%; adjusted hazard ratio=0.07, p = 0.018). In premenopausal women, CT benefit persisted only when adjuvant gonadotropin-releasing hormone analogue was not administered (p = 0.008), especially in N0/RI (p = 0.023). Results were confirmed after PSM. CT-treated N0/RH showed similar EFS to CT-treated N0/RI+N1/RL-RI, while N1/RH showed poor prognosis despite CT use. 5-year EFS rates were generally consistent with OncotypeDX® trials. Prosigna can help identify young women with stage I-II ER+ /HER2- BC who gain benefit from (neo)adjuvant CT and those in need of further escalated treatments. In premenopausal N0/RI and N1/RL-RI disease, the effect of CT seems to be driven by ovarian function suppression. Prospective validation is required.